Results 221 to 230 of about 1,532,404 (358)

Extravascular factor IX after gene therapy in hemophilia B, does it matter?

Research and Practice in Thrombosis and Haemostasis
Gene therapy will very likely change the treatment paradigm of hemophilia B in the coming years. For the majority of patients, adjunctive exogenous factor (F)IX clotting factor concentrate will continue to be needed in case of surgery or bleeding ...
Quentin Van Thillo, Cédric Hermans
doaj  

Genetic heterogeneity in response to adenovirus gene therapy. [PDF]

, 2003
Pierre Lefesvre, Joline Attema, Angelique A. C. Lemckert, Menzo Havenga, Dirk van Bekkum   +4 more
openalex   +1 more source

Human Gene Transfer: Some Theological Contributions to the Ethical Debate [PDF]

, 2001
Walter, James J.
core   +2 more sources

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Immunological needles in the gene therapy haystack: applying a genetic paradigm to gene therapy [PDF]

, 2003
PR Lowenstein
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Pharmacological treatment and BBB-targeted genetic therapy for MCT8-dependent hypomyelination in zebrafish.

Dis Model Mech, 2016
Zada D, Tovin A, Lerer-Goldshtein T, Appelbaum L.   +3 more
europepmc   +1 more source

From what should we protect future generations: germ-line therapy or genetic screening? [PDF]

, 2003
Pierre Mallia, Henk ten Have
openalex   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

In vivo imaging of molecular-genetic targets for cancer therapy [PDF]

, 2003
Juri G. Gelovani, Ronald G. Blasberg
openalex   +1 more source